Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 3

a concentration amore a copia you	
Application Number	10/716,976
Filing Date	November 19, 2003
First Named Inventor	O. Almarsson
Group Art Unit	1615
Examiner Name	T. McIntosh, III
Attorney Docket Number	MCN5003-USCNT2

		Sheet i di		U.S. PATENT DOCUMENTS		
	Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,
Examiner Initials			d Code ² known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
Sal)	4,513,006		Maryanoff et al.	04/23/1985	
		5,242,942		Costanzo et al.	09/07/1993	
		5,384,327		Costanzo et al.	01/24/1995	
		5,753,693		Shank	05/19/1998	
		5,760,007		Shank et al.	06/02/1999	
		5,952,187		Stenglein et al.	09/14/1999	
		5,935,933		Shank et al.	08/10/1999	
		5,998,380		Enhrenberg et al.	12/07/1999	
		6,071,537		Shank	06/06/2000	
		6,191,117		Kozachuk	02/20/2001	
		6,201,010	i	Cottrell	03/13/2001	
		6,319,903		Carrazana et al.	11/20/2001	
		6,503,884		Ehrenberg et al.	01/07/2003	
		6,559,293		Almarsson et al.	05/06/2003	
		US-2003/0069190		Abdel-Magid et al.	04/10/2003	
		5,498,629		Costenzo et al.	12/03/1996	
		6,323,236		McElroy	27/11/2001	
		US-2002/00424496		Dewey et al.	04/11/2002	
	/	US-2003/0072802		Cutler	04/17/2003	
SU(1)		US-2002/0037925		Dewey et al.	03/28/2002	·

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

Application Number	10/716,976
Filing Date	November 19, 2003
First Named Inventor	O. Almarsson
Group Art Unit	1615
Examiner Name	T. McIntosh, III
Attorney Docket Number	MCN5003-USCNT2

FOREIGN PATENT DOCUMENTS

			Foreign Patent Document		nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials		Cite No.¹	Office ³ Number ⁴ KindCode ⁵		ndCode⁵	Applicant of Cited Document	mṃ-dd-yyyy	passages or relevant figures appear	T⁵
<	9/		wo	00/50020	A2	University of Cincinnati	08/31/2000		
			WO	00/07583	A2	Brookhaven Science Associates	02/17/2000		
			wo	03/006467		Ortho-McNeil Pharmacueticals	23/01/2003		
			wo	03/070738		Transform Pharmacueticals	28/08/2003		,
5	91	1	wo	00/72841		Beriant, Jeffrey	05/26/2000		

Examiner Date Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

Examiner

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

a conection of information unless it displays	a valid Civib Control namber.
Application Number	10/716,976
Filing Date	November 19, 2003
First Named Inventor	O. Almarsson
Group Art Unit	1615
Examiner Name	T. McIntosh, III
Attorney Docket Number	MCN5003-USCNT2

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	_
Examiner's Cite Initials*	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
- 0	ROSENFELD, WILLIAM E. "Topiramate: A Review of Preclinical,	
34//	Pharmacokinetic, and Clinical Data", Clinical Therapeutics (1997), Vol. 19,	
	No. 6, pages 1294-1308.	
	Physician's Desk Reference, 56th Edition, pages 2590-2595, 2002.	
1	FAUGHT, E., et al., "Topiramate Dose-Ranging Trial in Refractory Partial	
	Epilepsy", Amer. Epilepsy Soc. Proc. (1995), Vol. 36, Supp. 4, page 33.	
	PRIVITERA, M., et al., "Dose-Ranging Trial with Higher Doses of Topmirate	
	in Patients with Resistant Partial Seizures", Amer. Epilepsy Soc. Proc.	
	(1995), Vol. 36, Supp. 4, page 33.	
	SACHDEO, S.K., et al., "Topiramate: Double-Blind Trial as Monotherapy",	
	Amer. Epilepsy Soc. Proc. (1995), Vol. 36, Supp. 4, page 33.	
I /	Press Release. "Clinical Development of Topiramate for Obesity Extended	
$\sim \sim \sim$	to Simplify Dosing, Improve Tolerability".	
\mathcal{I}	http://www.orthomcneil.com/news/article020402.html (February 4, 2002),	
	N.J.	
	·	
	·	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

Date

Considered